The economic burden of supportive care of cancer patients

Supportive Care in Cancer

Volumn 12, Issue 4, 2004, Pages 219-226

  Elting, Linda S ^a   Shih, Ya Chen Tina ^a  

^a UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

Author keywords

Anemia; Cancer; Cost; Diarrhea; Hemorrhage; Infection; Mucositis

Indexed keywords

CALCULATION; CANCER; CANCER CENTER; CANCER PALLIATIVE THERAPY; CANCER PATIENT; CANCER THERAPY; COST CONTROL; COST EFFECTIVENESS ANALYSIS; DIARRHEA; ECONOMIC ASPECT; HEALTH CARE COST; HEALTH CARE POLICY; HOSPITAL PATIENT; HOSPITALIZATION; HUMAN; MEDICAL CARE; MEDICAL DECISION MAKING; MEDICAL FEE; MEDICAL LITERATURE; MEDICARE; OUTPATIENT; OUTPATIENT DEPARTMENT; POPULATION; PRIORITY JOURNAL; PUBLICATION; REIMBURSEMENT; REVIEW; RISK; TREATMENT INDICATION; TREATMENT PLANNING; UNITED STATES;

AMBULATORY CARE; COST CONTROL; COST OF ILLNESS; COST-BENEFIT ANALYSIS; EPISODE OF CARE; HEALTH CARE COSTS; HOSPITALIZATION; HUMANS; MEDICARE; NEOPLASMS; PATIENT CARE; TEXAS; UNITED STATES;

EID: 2542487403     PISSN: 09414355     EISSN: None     Source Type: Journal    
DOI: 10.1007/s00520-003-0513-1     Document Type: Review

References (65)

1. Ackerman SJ, Klumpp TR, Guzman GI, et al (2000) Economic consequences of alterations in platelet transfusion dose: analysis of a prospective, randomized, double-blind trial. Transfusion 40:1457-1462
2. Attanasio E, Russo P, Carunchio G, Caprino L (2001) Dematan sulfate versus unfractionated heparin for the prevention of venous thromboembolism in patients undergoing surgery for cancer: a cost-effectiveness analysis. Pharmacoeconomics 19:57-68
3. Bank of Canada (2003) http:// www.bank-banque-canada.ca/pdf/ nraa98.pdf
4. Barosi G, Marchetti M, Liberato NL (1998) Cost-effectiveness of recombinant human erythropoietin in the prevention of chemotherapy-induced anaemia. Br J Cancer 78:781-787
5. Bennett CL, Weeks JA, Somerfield MR, Feinglass J, Smith TJ (1999) Use of hematopoietic colony-stimulating factors: comparison of the 1994 and 1997 American Society of Clinical Oncology surveys regarding ASCO clinical practice guidelines. J Clin Oncol 17:3676-3681
6. Adams JR, Elting LS, Lyman GH, George JN, Lembersky BC, Armitage JO, Demetri GD, Bennett CL (2004) Use of erythropoietin in cancer patients: assessment of oncologists' practice patterns in the United States and other countries. Am J Med 116:28-34
7. Bureau of Labor Statistics (2003) Consumer price index - medical care. US Department of Labor. http://www.bls. gov
8. Calhoun EA, Chang CH, Welshman EE, Fishman DA, Lurain JR, Bennet CL (2001) Evaluating the total costs of chemotherapy-induced toxicity: results from a pilot study with ovarian cancer patients. Oncologist 6:441-444
9. Cantor SB, Rubenstein EB, Elting LS, Frisbee-Hume S, Bratka CS, Stedman D, Rolston KVI (1997) Economic evaluation of management strategies for low-risk febrile neutropenic cancer patients. J Clin Oncol 16:419a
10. Caro JJ, Getsios D, Caro I, O'Brien JA (2002) Cost effectiveness of tinzaparin sodium versus unfractionated heparin in the treatment of proximal deep vein thrombosis. Pharmacoeconomics 20:593-602
11. Castagnola E, Paola D, Giacchino R, Rossi R, Viscoli C (1998) Economic aspects of empiric antibiotic therapy for febrile neutropenia in children with cancer. Support Care Cancer 6:524-528
12. Chaplin S (1991) Cancer therapy complications costly to treat. Hosp Doctor 9:30
13. Chevat C, Peňa BM, Maiwenn JAL, Rutten FFH (2001) Healthcare resource utilization and costs of treating NSAID-associated gastrointestinal toxicity: a multinational perspective. Pharmacoeconomics 19 [Suppl 1]:17-32
14. Comay D, Marshall JK (2002) Resource utilization for acute lower gastrointestinal hemorrhage: the Ontario GI bleed study. Can J Gastroenterol 16:677-682
15. Costa VC, Ferraz MB, Petrilli AS, Pereira CA, Rogerio JW (2003) Resource utilization and cost of episodes of febrile neutropenia in children with acute leukemias and lymphomas. Support Care Cancer 11:356-361
16. Dalton JD, Bailey NP, Barrett-Lee PJ, O'Brien MER (1998) Multicenter UK audit of anemia in patients receiving cytotoxic chemotherapy. Proc Am Soc Clin Oncol 17:418a
17. Delea TE, Vera-Llonch M, Edelsberg JS, et al (2002) The incidence and cost of hospitalization for 5-FU toxicity among Medicare beneficiaries with metastatic colorectal cancer. Value Health 5:35-43
18. Dimick JB, Pronovost PJ, Cowan JA, Lipsett PA (2003) Complications and costs after high-risk surgery: where should we focus quality improvement initiatives? J Am Coll Surg 196:671-678
19. Dranitsaris G, Tran MT, McGeer A, Narine L (1995) Pharmacoeconomic analysis of empirical therapy with ceftazidime alone or combination antibiotics for febrile neutropenia in cancer patients. Pharmacoeconomics 7:49-62
20. Drummond MF, Dubois D, Garattini L, et al (1999) Current trends in the use of pharmacoeconomics and outcomes research in Europe. Value Health 2:323-332
21. Elting LS, Cantor SB (2002) Outcomes and costs of febrile neutropenia: adventures in the science and art of treatment choices. Supp Care Cancer 10:189-196
22. Elting L, Gupta S, Kurtin D, Martin C, Rivera E, Salama V, Escalante C (1999) Outcomes of deep venous thrombosis (DVT) in cancer patients. Arch Intern Med (in press)
23. Elting LS, Rubenstein EB, Martin CG, Kurtin D, Rodriguez S, Laiho E, Kanesan K, Cantor SB, Benjamin RS (2001) Incidence, cost and outcomes of bleeding and chemotherapy dose modification among solid tumor patients with chemotherapy-induced thrombocytopenia. J Clin Oncol 19:1137-1146
24. Elting LS, Cooksley C, Chambers M, Martin C, Manzullo, E, Rubenstein E (2002) Outcomes of oral mucositis among cancer patients (abstract 34). Supp Care Cancer 10:363
25. Elting LS, Cantor SB, Martin CG, Hamblin L, Kurtin D, Rivera E, Vadhan-Raj S, Benjamin RS (2003) Cost of chemotherapy-induced thrombocytopenia among patients with lymphoma or solid tumors. Cancer 97:1541-1550
26. Escalante CP, Kurtin D, Rivera E, Elting LS (2000) Severity of illness, outcomes and resource utilization in elderly cancer patients with deep venous thrombosis. Clin Appl Thromb Hemost 6:175-178
27. ExchangeRate.com Inc. (2003) www.exchangerate.com. Accessed 10 June 2003
28. Forbes JM, Anderson GF, Anderson GC, Bleecker EC, Rossi EC, Moss GS (1991) Blood transfusion costs: a multicenter study. Transfusion 31:318-323
29. Fortner BV, Okon TA, Portenoy RK (2002) A survey of pain-related hospitalizations, emergency department visits, and physician office visits reported by cancer patients with and without history of breakthrough pain. J Pain 3:38-44
30. Garrelts JC, Horst WD, Silkey B, Gagnon S (1994) A pharmacoeconomic model to evaluate antibiotic costs. Pharmacotherapy 14:438-445
31. Glaspy JA, Bleecker GC, Stoller RG, Strauss MJ (1991) Decreased costs in cancer chemotherapy patients using recombinant granulocyte colony-stimulating factor (abstract). Clin Res 39:7A
32. Greer M (2001) Blood transfusion most cost-effective option for anemia treatment. Blood Weekly 11/15
33. Haddix AC, Shaffer PA (1996) Cost-effectiveness analysis. In: Haddix AC, Teutsch SM, Shaffer PA, Dunet DO (eds) Prevention effectiveness: a guide to decision analysis and economic evaluation. Oxford University Press, New York
34. Heckinger B, Lee J, Calhoun B, Bennett C (2003) The direct and indirect costs of febrile neutropenia: estimates based on community practice care in modern era. Proceedings American Society of Clinical Oncology Meeting, vol. 22
35. Jefferies LC, Sachais BS, Young DS (2001) Blood transfusion costs by diagnosis-related groups in 60 university hospitals in 1995. Transfusion 41:522-529
36. Kavanagh BD, Fischer BA, Segreti EM, Wheelock JB, et al (2001) Cost analysis of erythropoietin versus blood transfusions for cervical cancer patients receiving chemoradiotherapy. Int J Radiat Oncol Biol Phys 51:435-441
37. Leese B (1993) The costs of treating febrile neutropenia in six UK hospitals. Eur J Cancer 29A [Suppl 7]:15-18
38. Leese B (1994) The costs of treating febrile neutropenia in patients with malignant blood disorders. Pharmacoeconomics 6:233-239
39. Levit K, Smith C, Cowan C, Lazenby H, Martin A (2002) Inflation spurs health spending in 2000. Health Affairs 21:172-181
40. Lyman GH, Kuderer N, Greene J, Balducci L (1998) The economics of febrile neutropenia: implications for the use of colony-stimulating factors. Eur J Cancer 34:1857-1864
41. Maxwell GL, Myers ER, Clarke-Person C (2000) Cost-effectiveness of deep venous thrombosis prophylaxis in gynecologic oncology surgery. Obstet Gynecol 95:206-214
42. Meadowcroft AM, Gilbert CJ, Maravich-May D, et al (1998) Cost of managing anemia with and without prophylactic epoetin alfa therapy in breast cancer patients receiving combination chemotherapy. Am J Health Syst Pharm 55:1898-1902
43. Meehan KR, Matias CO, Rathore SS, Sandler SG, Kallich J, LaBrecque J, Erder H, Schulman KA (2000) Platelet transfusions: utilization and associated costs in a tertiary care hospital. Am J Hematol 64:251-256
44. Minotti V, Gentile G, Bucaneve G, et al (1999) Domiciliary treatment of febrile episodes in cancer patients: a prospective randomized trial comparing oral versus parenteral empirical antibiotic treatment. Support Care Cancer 7:134-139
45. Monte ED, Belmont MJ, Wax MK (1999) Management paradigms for posterior epistaxis: a comparison of costs and complications. Otolaryngol Head Neck Surg 121:103-106
46. Nuijten MJC, Berto P, Berdeaux G, et al (2001) Trends in decision-making process for pharmaceuticals in Western European countries. HEPAC 2:162-169
47. O'Brien JA, Caro J (2002) Direct medical cost of managing deep vein thrombosis according to the occurrence of complications. Pharmacoeconomics 20:603-615
48. Office of the Federal Register, National Archives and Records Administration (2001) Federal Register 66:40077-40102
49. Ortega A, Dranitsaris G, Puodziunas AL (1998) What are cancer patients willing to pay for prophylactic epoetin alfa? A cost benefit analysis. Cancer 83:2588-2596
50. Peterman A, Cella D, Glandon G, Dobrez D, Yount S (2001) Mucositis in head and neck cancer: economic and quality-of-life outcomes. J Natl Cancer Inst Monogr 29:45-51
51. Ruchlin HS, Dasbach EJ (2001) An economic overview of chronic obstructive pulmonary disease. Pharmacoeconomics 19:623-642
52. Sheffield R, Sullivan SD, Saltiel E, et al (1997) Cost comparison of recombinant human erythropoietin and blood transfusion in cancer chemotherapy-induced anemia. Ann Pharmacother 31:15-22
53. Shulkin DJ, Kinosian B, Glick H, Glen-Puschett C, et al (1993) The economic impact of infections. An analysis of hospital costs and charges in surgical patients with cancer. Arch Surg 128:449-452
54. Sonis ST, Oster G, Fuchs H, Bellm L, Bradford WZ, Edelsberg J, et al (2001) Oral mucositis and the clinical and economic outcomes of hematopoietic stem-cell transplantation. J Clin Oncol 19:2201-2205
55. Stewart DJ, Dahrouge S, Coyle D, Evans WK (1999) Costs of treating and preventing nausea and vomiting in patients receiving chemotherapy. J Clin Oncol 17:344-351
56. Sullivan SD, Ramsey SD, Lee TA (2000) The economic burden of COPD. Chest 117 [2 Suppl]:5S-9S
57. Torrance G, Walker V, Grossman R, Mukherjee J, Vaughan D, LaForge J, Lampron N (1999) Economic evaluation of ciprofloxacin compared with usual antibacterial care for the treatment of acute exacerbations of chronic bronchitis in patients followed for 1 year. Pharmacoeconomics 16:499-520
58. Turini M, Redaelli A, Gramegna P, Radice D (2003) Quality of life and economic considerations in the management of prostate cancer. Pharmacoeconomics 21:527-541
59. Uyl-de Groot CA, Vellenga E, de Vries EGE, Lowenberg B, et al (1997) Treatment costs and quality of life with granulocyte-macrophage colony-stimulating factor in patients with antineo-plastic therapy-related febrile neutropenia. Pharmacoeconomics 12:351-360
60. Wahlqvist P, Junghard O, Higgins A, Green J (2002) Cost effectiveness of esomeprazole compared with omeprazole in the acute treatment of patients with reflux oesophagitis in the UK. Pharmacoeconomics 20:279-287
61. Wang ECY, Grasela TH, Walawander CA (1999) Applying epidemiology-based outcomes research to clinical decision-making: a hypothetical model of biotechnology therapy in gram-negative sepsis. Pharmacoeconomics 15:385-393
62. Ward MM, Javitz HS, Smith WM, et al (2000) Direct medical cost of chronic obstructive pulmonary disease in the U.S.A. Respir Med 94:1123-1129
63. Weimar C, Weber C, Wagner M, Busse O, et al (2003) Management patterns and health care use after intracerebral hemorrhage: a cost-of-illness study from a societal perspective in Germany. Cerebrovasc Dis 15:29-36
64. Wilson L, Devine EB, So K (2000) Direct medical costs of chronic obstructive pulmonary disease: chronic bronchitis and emphysema. Respir Med 94:204-213
65. Zabinski RA, Burke TA, Johnson J, Lavoie F, Fitzsimon C, Tretiak R, Chancellor JVM (2001) An economic model for determining the costs and consequences of using various treatment alternatives for the management of arthritis in Canada. Pharmacoeconomics 19 [Suppl 1]:49-58